PubMed · 16121684
Recent developments in glycopeptide antibacterials.
Abstract
The glycopeptide class of antibiotics, namely vancomycin and teicoplanin, are intravenously administered in the hospital setting for the treatment of the most severe of Gram-positive infections. Although a mainstay of the hospital formulary for over four decades, the rise of increasingly frequent high-level vancomycin resistance in enterococci and low-level resistance in staphylococci (as well as a few high-level vancomycin resistance cases) has highlighted the need for the identification of naturally occurring and semi-synthetically modified glycopeptide derivatives that have antibacterial activity against these resistant strains. Among the leading development candidates are dalbavancin, oritavancin, telavancin and ramoplanin, each of which provides a unique microbiological and pharmacological profile to fill an important unmet medical need.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
John F Barrett. 2005. Recent developments in glycopeptide antibacterials.. https://pubmed.ncbi.nlm.nih.gov/16121684/
Cite the original work for its findings. Save a collection to share your selection of sources.